Abstract
The prognosis of breast cancer is strongly influenced by the stage of the disease; therefore, it is essential that breast cancer lesions be diagnosed at the earliest stages. There is an urgent need to identify different biomarkers with a high accuracy for the early detection of this cancer to facilitate clinical management of the disease. A wide number of substances named serum tumor markers can be detected in the serum of patients with breast cancer, including tumor-associated proteins, cytokines, stimulating or inhibiting factors, autoantibodies to antigen tumor-associated substances and miRNAs. Despite ASCO and NACB recommendations, the routine use of breast cancer tumor markers by a significant proportion of oncologists is common, particularly after primary treatment of early tumors. The new promising circulating markers are HER2/neu, Trx 1, CSF1, autoantibodies against these tumor-associated antigens, and miRNAs, which are non-coding RNA molecules that regulate the translation of mRNA and control a number of biological processes, including oncogenic cells proliferation. The expression of single miRNA results in a miRNA signature, and is considered a potential biomarker for early breast cancer. However, additional studies are needed to identify its real usefulness.
Keywords: Early breast cancer, biomarker, serum tumor markers, ELISA, HER2, Trx1, CSF1, MicroRNA.
Medicinal Chemistry
Title:Serum Tumor Markers in Stage I-II Breast Cancer
Volume: 12 Issue: 3
Keywords: Early breast cancer, biomarker, serum tumor markers, ELISA, HER2, Trx1, CSF1, MicroRNA.
Abstract: The prognosis of breast cancer is strongly influenced by the stage of the disease; therefore, it is essential that breast cancer lesions be diagnosed at the earliest stages. There is an urgent need to identify different biomarkers with a high accuracy for the early detection of this cancer to facilitate clinical management of the disease. A wide number of substances named serum tumor markers can be detected in the serum of patients with breast cancer, including tumor-associated proteins, cytokines, stimulating or inhibiting factors, autoantibodies to antigen tumor-associated substances and miRNAs. Despite ASCO and NACB recommendations, the routine use of breast cancer tumor markers by a significant proportion of oncologists is common, particularly after primary treatment of early tumors. The new promising circulating markers are HER2/neu, Trx 1, CSF1, autoantibodies against these tumor-associated antigens, and miRNAs, which are non-coding RNA molecules that regulate the translation of mRNA and control a number of biological processes, including oncogenic cells proliferation. The expression of single miRNA results in a miRNA signature, and is considered a potential biomarker for early breast cancer. However, additional studies are needed to identify its real usefulness.
Export Options
About this article
Cite this article as:
Serum Tumor Markers in Stage I-II Breast Cancer, Medicinal Chemistry 2016; 12 (3) . https://dx.doi.org/10.2174/1573406412666151116144520
DOI https://dx.doi.org/10.2174/1573406412666151116144520 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Approaches to Profile Functional Long Noncoding RNAs Associated with Stem Cell Pluripotency
Current Genomics Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review
Current Medicinal Chemistry Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry Effect of Paclitaxel-Loaded PLGA Nanoparticles on MDA-MB Type Cell Lines: Apoptosis and Cytotoxicity Studies
Current Pharmaceutical Design Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Synthesis and Medicinal Applications of Benzimidazoles: An Overview
Current Organic Synthesis Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics Natural Sesquiterpene Lactones in the Prevention and Treatment of Inflammatory Disorders and cancer: A Systematic Study of this Emerging Therapeutic Approach based on Chemical and Pharmacological Aspect
Letters in Drug Design & Discovery Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer
Current Drug Targets Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Digital Mammograms with Image Enhancement Techniques for Breast Cancer Detection: A Systematic Review
Current Medical Imaging Development of Folate-Conjugated PEGylated Poly (d,l-lactide-co-glycolide) Nanoparticulate Carrier for Docetaxel
Current Nanoscience Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders
Current Drug Targets Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Anti-Cancer Agents in Medicinal Chemistry siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy